Novartis AG is the latest big pharma company to collaborate on the development of novel inhibitors of KRAS, cellular signaling proteins which when mutated have been widely linked to the development of cancer but previously found difficult to design drugs against.
In a multi-year agreement, Novartis will advance novel KRAS inhibitors discovered by researchers at Cancer Research UK’s Beatson Institute in...








